IMNM
Immunome, Inc.NASDAQHealthcare$21.84-2.72%OpenMarket Cap: $1.92B
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.01
P/S
276.46
EV/EBITDA
-6.08
DCF Value
$7.38
FCF Yield
-10.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
-630.3%
Operating Margin
-3084.8%
Net Margin
-3060.0%
ROE
-57.6%
ROA
-31.1%
ROIC
-33.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-69.9M | $-0.76 |
| FY 2025 | $6.9M | $-212.4M | $-2.43 |
| Q3 2025 | $0.00 | $-57.5M | $-0.65 |
| Q2 2025 | $4.0M | $-43.4M | $-0.50 |
Analyst Ratings
View AllStephens & Co.Overweight
2026-03-04Craig-HallumBuy
2026-03-04WedbushOutperform
2026-01-15GuggenheimBuy
2025-12-16Evercore ISI GroupOutperform
2025-12-16Trading Activity
Insider Trades
View AllRosett Maxofficer: Chief Financial Officer
SellFri Apr 03
Rosett Maxofficer: Chief Financial Officer
SellFri Apr 03
Rosett Maxofficer: Chief Financial Officer
SellFri Apr 03
Rosett Maxofficer: Chief Financial Officer
SellFri Apr 03
Higgins Jackofficer: Chief Scientific Officer
SellFri Apr 03
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.14
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.